2020 ESMO Lung Cancer Progress Large Inventory.

Affected by the new crown outbreak, the 2020 ESMO Annual Meeting will be held in the form of an online virtual meeting.
unexpectedly, the field of lung cancer ushered in a wave of new progress, today specially organized the field of lung cancer some important research progress, in order to meet everyone.
1. Early safety data from the FLAURA2 study were published, Oghithini combined chemotherapy is good for first-line safety Based on FLAURA results, oxytinib has become a first-line treatment preferred for EGFR mutation-positive late NSCLC, and the FLAURA2 (NCT04035486) study aims to explore the efficacy and safety of oghithinib combination or non-combined chemotherapy for first-line therapy.
early security data from the FLAURA2 study was released at the ESMO Annual Meeting.
data as of February 2020, a total of 30 patients were included in the Oghitini combined chemotherapy group: Oghitini combined with pythonse and carabin (n=15), Oghitini combined with esotonics and cisplatin (n=15).
27 patients (90%) had any adverse events, and 2 (7%) patients had their treatment interrupted due to adverse events, including 1 case of level 2 dose-limiting toxicity and 1 case unrelated to treatment, attributed to the fatal toxicity of the disease (healing).
37% (11/30) of the overall population was 37%.
safety data from theURA2 study show that Oghitini's combined Pyme curvature and carptin/cisplatin tolerances are good, supporting further evaluation of the efficacy and safety of the program in the study.
2. ASCEND-8 Asian population study data, Seritinie 450mg with meal drug efficacy and safety was confirmed ASCEND-8 study based on the intention to treat the population data have shown that Ceritiniry 450mg with meal delivery treatment regimen tolerance effectiveness.
the ESMO Annual Meeting, ASCEND-8 Research Asia Population Data was released.
data as of March 6, 2020, out of a total of 74 Asian patients included, BIRC assessed that the 450 mg on-the-food delivery group had a higher ORR, medium DOR, and medium PFS than 750 mg on an empty stomach.
three-year OS rate was 93.1% and 70.9%, respectively.
the rates of gastrointestinal toxicity were 82.8%, 78.9% and 96.2% in the three groups of 450mg follow-up drug delivery group, 600mg follow-up drug delivery group and 750mg on-the-food dosage group, respectively, and 3.4%, 5.3% and 7.7% respectively.
, 450 mg of follow-up drug delivery showed digitally better efficacy and lower gastrointestinal toxicity than 750 mg of prescription on an empty stomach in the Asian ALC-positive late NSCLC population.
3.MET inhibitor Capmatinib combined with third-generation EGFR-TKI Nazartinib to treat EGFR mutation NSCLC This multi-center I.b/II. phase study aims to explore the efficacy and safety of Capmatinib combined with Nazartinibl for EGFR mutation NSCLC.
study was divided into three groups, with treated patients with any T790M/MET changes (group 1), untreated patients with T79OM negative, and patients with any MET changes (group 3).
data as of February 5, 2019, groups 1 and 3 included 52 and 47 patients, respectively.
ORR was 28.8% in patients treated in group 1, ORR was 61.7% in patients in untreated group 3, ORR was 43.5% in patients with MET-positive (IHC 3 plus and/or gene copy number of 4), and ORR was 27.9% in MET-negative patients.
safety, adverse events associated with treatment at any level with a frequency of 30% (group 1, group 3) were exoded edema (50%, 57.4%), nausea (42.3%, 48.9%) and diarrhea (23.1%, 46.8%).
4. Bugatinib First Line: First-line Bugatinib vs. Kerotinib in Asian and non-Asian patients: ALTA-1L Update ALTA-1L (NCT02737501) Second Interim Analysis (IA2) report the latest data on the use of ALK TKI for the treatment of ALK and NSCLC in Asian and non-Asian patients.
275 patients were randomly selected, 108 Asia (BRG / CRZ, n s 59/49), 167 non-Asian (n s 78/89);
results show that among Asian populations, biRC assessed BRG-medium PFS (mPFS) at 24.0 mo (95% CI 18.4-not up to nR), while CRZ mPFS is 11.1 mo (9.2-15.6) (HR 0.38 (95% CI 0.22-0.65); P - 0.0006).
among Asians, (BRG/CRZ) confirmed ORR (95%CI) as 78% (65-88)/ 71% (57-83), P s 0.3397;
asia and non-Asian regions, the duration of the BRG group iPFS is longer.
security situation for Asians and non-Asians is similar.
5. In the late NSCLC:GEOMETRY II study of the immunotherapy METex14 mutation, in the Phase II GEOMETRY mono-1 study, Carmatini was 68% ORR in the untreated METex14 NSCLC and 41% in patients treated with first/second-line treatment.
this study evaluates the efficacy of carmatinini in treating immunothermed patients.
study included 69 METex14 NSCLCs.
of these cases, 19 had used IO (middle age 71; female 63.2 per cent; non-smoker 63.2 per cent) and 50 had not used IO (medium age 71.5 years; female 56 per cent; non-smoker 56 per cent).
the average tumor mutation load of 10 mut / mb in both groups, 9 out of 19 patients with past IO received IO first-line treatment and 10 second-line received IO single treatment.
14/19 is unresponsive to IO.
previous IO had a median PFS of 3.29 months (95% CI 2.10-5.16).
results showed that orR for patients treated with and without IO was 57.9% (n s 11/19; 95% CI 33.5-79.7) and 34% (n s 17/50; 95% CI 21.2-48.8) respectively; The median DOR is 11.20 months (95% CI 3.35-NE) and 7.16 months (95% CI 4.17-11.14), respectively.
no increased risk of mesostic lung disease/pneumonia.
6. The efficacy of ntRK/ROS1-positive companion CNS metastasis NSCLC In 13 assessable NTRK-fp NSCLC patients, the medium age was 60 years old, 53.8% in women and 69.2% in adenocarcinoma.
8 cases (61.5%) of CNS lesions when the baseline was used.
patients who received pre-brain radiotherapy (RT) were 5 (38.5%), of which 3 completed RT for 2 months before enthatinib.
of the 161 assessable ROS1-fp NSCLC patients, the medium age was 54 years, 64.6% were women and 96.9% were adenocarcinoma.
46 cases (28.6%) of the baseline central nervous system lesions.
27 patients (16.8%) received brain radiotherapy, of which 10 completed radiotherapy for up to 2 months before ententini.
NTRK/ ROS1 orR was 62.5% and 52.2%, respectively, and PFS was 8.9 months and 8.3 months, respectively, in consistent with previously reported security.
7.LAG3 Monoantigen-K drug first-line treatment of patients with PDL1 insoluble non-small cell lung cancer Eftilagimod alpha (efti) is a soluble LAG-3 protein that mediates antigen delivery cell (APC) activation and CD8 T cell activation.
study included NSCLC patients who had never been treated for PDL1 insanity.
two-part, phase 1 recruited 17 patients to reach a pre-set threshold.
19 patients were recruited in Phase 2.
8 cycles of Efti injections every 2 weeks, followed by 9 cycles every 3 weeks, and the use of K medicine (200 mg infusion every 3 weeks for 2 years).
results show that all patients in Stage 1 (n s 17) are assessable.
9 patients (53%) reached PR, 5 patients (29%) SD, ORR and DCR 53% and 82%, respectively.
reactions were observed in all PD-L1 subgroups.
most common adverse events were cough (29%), fatigue (24%), decreased appetite (18%), breathing difficulties (18%), fatigue (17%), diarrhea (15%) and nausea (12%).
41% of patients are still receiving treatment and have not reached the mid-level PFS (follow-up for more than 9 months).
8. The efficacy of local late/metastasis non-scaly NSCLC in the first-line treatment of Terelliju monotherapy vs chemotherapy In this open-label Phase 3 study (NCT03663205), Chinese patients were randomly divided into 2:1 ratios to receive Terelliju single Anti-platinum and permeable curvature therapy, and then maintain the A arm (n-223) of the reilly-pearl monoanti-Pemcoser, and the B-arm (n-111) that received the platinum-pemonics and the maintenance therapy of the pyrethroids.
the main research endpoints are PFS assessed by the Independent Review Commission (PFS IRC), and secondary endpoints include ORR, DoR, and safety/tolerance.
results showed that the meso-PFS of single-anti-combination therapy for Reilly was significantly longer than chemotherapy alone (9.7 months vs 7.6 months, P=0.0044; HR : 0.645, 95% CI: 0.462, 0.902).
combined chemotherapy group ORR was 57% (95% CI: 50.6, 64.0) and 37% (95% CI: 28.0, 46.0) respectively 6); The medium DoR is 8.5 months (95% CI: 6.80, 10.58) and 6.0 months (95% CI:4.99, NE), respectively.
group and chemotherapy group were 63% and 46%, respectively.
four patients (1%) had fatal pneumonia.
three of these may be related to the single resistance of The Reilly Pearl.
9. Simipri monoanti-Ipimu monoantigen second-line treatment of late NSCLC Phase II randomized, open-label study 27 patients with late NSCLC were randomly assigned (1:1:1; strated by histology and PD-L1 condition), receiving Semipri mono-resistance 350 mg (Arm A, n, 8) every 3 weeks (Q3W) or every 6 weeks (Q6W) Simipri monoanti (Q3W Gheilimu monoantigen resistance 50 mg (up to 4 doses) (arm B, n s 11) or simipri monoantigen 1050 mg Q3W (Arm C, n s 8), the main endpoint is PD-L1 expression and lt;50% of patients with objective remission rate (ORR).
results show that the ORR (95% confidence interval) in Group A is 0% (0.0-36.9%), Group B is 45.5% (16.7-76.6%) and Group C is 11.1% (0.3-48.2%).
ORR was 36.4% (B) and 11.1% (C) for PD-L1 patients and 9.1% (B) and 0% (C) for patients with PD-L1 levels of 1-49%.
DOR has not yet been reached.
only 1 patient in Group B reported elevated level 3 alanine transaminase.
source: 1.Planchard D, et al. Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study (EB/OL). ESMO 2020, abstract 1401P. 2.Cho BCC, et al. Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK plus non-small cell lung cancer (NSCLC) in the ASCEND-8 trial . ESMO 2020, abstract 1348P. 3.FelipE, et al. MET resor capmatinib plus EGFR tyrosine kinase or nazartinib for EGFR-mutant-small cell lung cancer ( EB/OL) . ESMO 2020, ab.